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Abstract 
Prostate cancer is a leading cause of death in males aged fifty and over. 
Glutathione transferase (GST) activity is depressed in prostate cancer cells. The 
aim of this study was to assess GST reactivation in LNCaP prostate cancer cells 
treated with curcumin or 5-azacitidine (5-Aza) which is a known hypomethylation 
agent. GST activity was determined using monochlorobimane (MCB). Cell 
viability was assessed with resazurin (Vision blue TM) or 3-(4, 5-Dimethyl- 
thiazol-2-yl)-2, 5-di-phenyltetrazolium- bromide (MTT). From the results, 
treatment with >5 μM of curcumin or 5-Aza for 3 or 6 days depressed LNCaP cell 
viability.  The concentrations of curcumin leading to 50% reduction of LNCaP 
cell viability (IC50) was 10-25 μM or 2-3 μM for 3 days or 6 days of treatment, 
respectively. The IC50 with 5-Aza was 17-23 μM (3 days) or 50-52 μM (6 days). 
Combination treatment using curcumin and 5-Aza showed complimentary 
interactions affecting cell viability. Low levels of curcumin or 5-Aza had no effect 
on GST activity. By contrast, cytotoxic doses of curcumin or 5-Aza increased 
GST activity by 450-750 % (3days) or 161-2800 % (6days). In conclusion, GST 
reactivation was feasible but only when LNCaP prostate cancer cells were treated 
with cytotoxic doses of curcumin or 5-azacytidne. 
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1 Introduction 
Prostate cancer is the leading gender-specific cancer in males with 90% of 
cases occurring over the age 50. The incidence of prostate cancer is higher in 
Western countries compared to South-Central-East Asian countries. Studies from 
developed countries suggest that males of black-African descent have a higher 
risk of developing prostate cancer as compared to their White and Asian 
colleagues [1]. Glutathione-S-transferase-pi (GST) expression is depressed in 
prostate tumors compared to benign prostate hyperplasia and normal prostate 
tissue due to gene silencing by epigenetic modifications [2, 3]. Hypermethylation 
affects GST expression, other tumor suppressor genes and various cancer-related 
processes: DNA repair, androgen responsiveness, cell cycle progression and 
metastases [4]. 
The GST superfamily comprises enzymes that protect healthy cells from 
reactive oxygen species (ROS), exogenous toxins, and cytotoxic agents. 
Inactivation of GST can create a deficit of detoxification capacity and increase 
tissue susceptibility towards carcinogens and ROS [5]. Restoration of GST 
activity was reported using 5-azacytidine (5-Aza; Vidaza TM) or deoxy-5 
deoxycytidine (Decitabine TM) as hypomethylation agents [6, 7] though such 
drugs have significant side-effects [7, 8].  Dietary hypomethylation agents are 
now attracting attention in-part because of their expected lack of side-effects [9, 
10] and potential for applications as nutraceuticals.  
Curcumin (diferuloylmethane), the spice component from Curcuma longa 
(Turmeric), possess anticancer activity (for review see [11-13].  Curcumin 
impairs the growth and survival of androgen sensitive LNCaP and androgen 
independent DU145 prostate cells [14-18]. More recently, curcumin was 
identified as a dietary hypomethylation agent via docking simulations and 
cell-based assays [19]. Other investigations found also that GST expression 
increases following treatment of LNCaP cells with green tea phenol extracts, 
epigallogatechin gallate (EGCG) [20, 21], phenethyl isothiocyanate [22], 
selenium [23], genistein and daidzein [24, 25]. However, whether curcumin 
induces GST expression in prostate cancer cells has not been thoroughly studied.  
In the present investigation, it was hypothesized that treatment of LNCaP prostate 
cancer cells with curcumin would result in the reactivation of GST activity. The 
experimental design features curcumin comparison with 5-Aza as a known 
hypomethylation agent and positive control. 
 
2 Materials and Methods 
Curcumin (>98% pure), 5-Azacytidine (5-Aza: >98% pure),  monochloro- 
bimane (MCB) , 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT), Resazurin (Vision blue TM) , dimethyl Sulfoxide (DMSO) and other 
chemicals were obtained from Sigma-Aldrich and stored at temperature  -20 oC. 
Human prostate cancer cell lines (LNCaP) were obtained from American type cell 
culture collection. Cell culture medium RPMI 1640 1X (Stored at 1-5 oC), Fetal 
bovine serum (FBS) (Stored at below -5 oC), Penicillin-Streptomycin solution 
(Stored at 1-5 oC), Trypsin 1X (Stored at below -18 oC), and Phosphate Buffer 
Saline tablets were from GIBCO® Laboratories (Invitrogen Ltd, UK).  
 
Cell culture   
LNCaP prostate cancer cells were cultured using RPMI 1640 supplemented 
with 10% FBS, 1% penicillin-streptomycin. Culture flasks and 96-well micro 
plates were incubated at 37 oC in a 5% CO2 atmosphere (LEEC research incubator; 
LEEC, UK). All cell culture operations were performed in a laminar flow cabinet 
(Air flow service, UK). Cells were trypsinized, counted using a NucleoCounter 
(model NC-3000, ChemoMetec, Denmark) and seeded (10,000 cells/ well) in 
96-microwell plates with 50 μl of culture medium overnight at 37°C to allow 
attachment.  
Curcumin and 5-Aza stock solutions (10mM) were prepared by dissolving 
with dimethyl sulfoxide (DMSO), diluting with culture medium 10-fold, and 
filter-sterilizing with 0.20-μm cellulose acetate filters. The sterile solution of 
curcumin or 5-Aza (1.0 mM) was further diluted with culture media to obtain the 
concentrations of 0.1, 1, 10, and 100 μM. Cells were treated with various 
concentrations of curcumin or 5-Aza (0-100 μM; 50 μl) and incubated at 37°C for 
3days or 6 days (72-144 hr). In these tests, the residual concentration of DMSO 
was <0.5%. For combination studies, cells were treated with a 50:50 mixture 
prepared from 20 μM curcumin and 20 μM of 5-Aza. Cells were treated with 
combination solutions which were 10 μM with respect to curcumin and 5-Aza. All 
other techniques were as described previously. 
 
Multiplex fluorescence assay for LNCaP cell viability and GST status 
In this investigation, cell viability was determined using resazurin (Vision 
blue) as described by Ahmed et al. [26] and GST was determined essentially as 
described by Kamencic et al [27] with modification.  For a multiplex 
fluorescence assay, cultured cells were washed three times with ice-cold PBS (100 
μl) to remove growth media, 5-aza or curcumin. The wells were covered with 50 
μl PBS and then 5 μl of a 50:50 mixture resazurin and MCB was added to cells 
followed by 2 hr incubation at 37°C. Fluorescence readings were measured at 
excitation wavelength (λex) of 530-570 nm and emission wavelength (λem) of 
590-620 for cell viability detection. A second set of fluorescence readings were 
also recorded with λex = 360 nm and λem = 535 nm to detect the cellular GST 
activity.  The fluorescence assays employed the Fluostar Omega Instrument 
(BMG-Lab-Tech, Germany). 
 
MTT assay for cell viability 
The MTT assay for cell viability was performed as described previously [28] 
with minor modification. Culture medium without / with curcumin or 5-Aza was 
removed by washing cells three times with ice-cold PBS (100 μl) prior to addition 
of 20 μl MTT. Then microwell plates were incubated for 2 hr at 37°C and then 
treated with 100 μl of lyses buffer (5% sodium dodecyl sulfate in 50% dimethyl 
formamide) for 24 hr to dissolve the blue formazan crystals formed. Absorbance 
was measured at 570 nm using a microplate reader (Tuneable VERSA Max MTT 
Micro plate reader; Molecular Devices, USA). 
 
Statistical Procedures 
Data are expressed as mean +SEM of three independent experiments in case 
of curcumin and two independent experiments for 5-Aza. One–way ANOVA 
testing (SPSS) was used to analyze significant statistical differences with Tukey 
post hoc analysis. P<0.05 were considered to be statistically significant.  
 
3. Results and Discussion 
The rate of development of prostate cancer is slow suggesting that this may 
be suitable for chemoprevention, by one of the following mechanisms:  inhibition 
of phase I enzymes for carcinogens activation, induction of GST and other phase II 
enzymes for detoxification, and/ or modulation of cell-cycle  progression, 
survival, apoptosis, angiogenesis or metastasis [10, 29, 30]. The enzyme GST is 
repressed in prostate cancer cells due to hypermethylation [2, 31-33]. Therefore, 
reactivation of GST is a potentially useful strategy for identifying hypomethylation 
agents [7]. In support of this thesis, several dietary agents were demonstrated to 
increase GST expression in LNCaP cells [20-25].  In view of recent reports 
concerning the role of curcumin as a hypomethylation agent [19], we examined the 
effect of this agent on cell viability and GST enzyme activity in LNCaP prostate 
cancer cells. 
  
Curcumin and 5-Azacytidine decrease LNCaP cell viability  
This study showed that curcumin and 5-Aza reduce LNCaP cell viability at 
concentrations >5 μM (Figure 1).  LNCaP cell viability changes observed using 
the resazurin assay (Figure 1) were similar to those observed using the MTT assay 
(data not shown).  The concentration of curcumin leading to 50% reduction of cell 
viability (IC50) is shown in Table 1. For curcumin the IC50 values decreased with 
increasing treatment time.  The IC50 for 3 days treatment (this study) agrees with 
20-30 μM reported for LNCaP cells treated with curcumin for 3-days [14]; 
however, the IC50 was 50±9 µM with two days of curcumin treatment [34]. The 
cytotoxicity of 5-Aza towards LNCaP cells has not been extensively studied. Thus, 
El Yagoobu found that >5 µM of 5-Aza was cytotoxic towards LNCaP cells but no 
IC50 values were reported [35]. Fesuccia et al showed that 5-Aza decreases LNCaP 
cell proliferation (IC50 =1.5 mM) however the drug exposure time was not defined 
[36]. The IC50 value for 5-Aza (Table 1) are ~100-fold higher compared to the 
IC50 reported for 5-aza-2’deoxycytidine [7] but the two drugs have differential 
modes of action. 
Combination studies were performed to determine whether treatment with a 
mixture of agents was advantageous compared with using curcumin or 5-Aza alone.  
Treatments using a mixture of curcumin and 5-Aza showed evidence of positive 
interactions at one day and 3 days exposure (Figure 2).  At longer exposure times 
(6 days; 144hr) there was no difference in the cytoxicity of curcumin or 5-Aza 
alone or in combination (Figure 2).  
Curcumin inhibition of LNCaP cell proliferation was time-dependent 
(Figure 1 & 2). Increasing the treatment time from 3 days to 6 days decreased the 
IC50 for curcumin by 10-fold (Table 1). However, the IC50 value for 5-Aza 
increased by ~2-fold with increasing time of treatment.  According to published 
data, LNCaP cell viability should decrease exponentially as a function of curcumin 
treatment time between 0-3 days [14, 16].  The time-course for LNCaP growth 
inhibition may also depend on the instability of curcumin.  In buffer solution (pH 
7.0) curcumin undergoes auto-oxidation with a half-life of 9.5 min increasing to 
119 min at pH 3.0 [37]. Dissolution with RPMI60 cell culture media containing 
10% FBS raised the half-life of curcumin to ~8hr [37] and so ~ 90% of curcumin 
would oxidise in 24hr in the presence of culture media. It has been proposed that the 
anticancer activity of curcumin is due partly to one or more of its auto-oxidation 
products [38, 39]. 
Curcumin and 5-Azacytidine increase GST activity from LNCaP cells  
The multiplex fluorescence assay for GST allowed adjustments for cell 
cytotoxicity (Figure 1) using resazurin fluorescence readings. Figure 3, shows that 
low doses of curcumin or 5-Aza produced no significant increases in the cell GST 
status. However, cytotoxic doses (50 μM) of curcumin or 5-Aza produced 
significant increases in GST activity (P <0.05) of 450-750 % (3 days) or 161-2800 
% (6 days). Cytotoxic doses (this study) or repeated low doses of nucleoside 
hypomethylation agents [31, 35] were required for reactivation of GST in LNCaP 
cells. Phytochemicals produce epigenetic or growth inhibitory effects depending on 
the concentration-time combinations used for treatment [23, 31, 35]. 
In conclusion, evidence presented in this study suggests that treating 
LNCaP prostate cancer cells with curcumin increases cellular GST activity.  
Analogous results were observed for LNCaP cells treated with 5-Aza which is an 
established hypomethylation agent. Cytotoxic doses of curcumin or 5-Aza were 
necessary for GST reactivation. The findings are similar to those reported for the 
induction of GST in breast cancer cells [40], as well as for phase II enzyme 
induction in other transformed cell lines [34]. Curcumin may function not only as a 
hypomethylation agent [19] but also as a “classical” chemopreventive agent via the 
Nuclear Factor-Erythroid 2-Related Factor 2 /antioxidant responsive element 
(Nrf2/ARE) pathway [16-18, 41]; detailed discussion of which mechanism 
predominates for curcumin bioactivity in LNCaP cells is beyond the scope of this 
paper though recent evidence suggests there may be cross-talk between the 
different pathways [42].  A chief limitation for this work is that there were no 
direct measurements of DNA-methylation.  Further research is needed also into 
factors which determine the effectiveness of dietary hypomethylation agents. 
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Table 1: Inhibition of prostate cancer LNCaP cell growth by curcumin or 
5-azacytidine for LNCaP prostate cancer cells  
 
 IC50 (μM) 
Treatment time  CURCUMIN  5-AZACYTIDINE  
3 days 10-25 17-23 
6 days 2-3 50-52 
 





Figure-1: Effect of curcumin or 5-azacytidine on LNCaP cell viability. Data shows 
means+ SE (n=12-16 data points). Bars with different letters are significantly 



































Curcumin OR 5-Azacytidine (µM) 
5-Azacytidine(control) treatment time(72 hrs)
5-Azacytidine(control) treatment time(144 hrs)
Curcumin treatment time(72 hrs)
Curcumin treatment time(144 hrs)
 
Figure-2: Effect of curcumin or 5-azacytidine or their combination on LNCaP 
cell viability.  Bars with different letters are significantly different (P<0.05).  
 
 
Figure 3: Effect of curcumin or 5-azacytidine on LNCaP glutathione–S 
-transferase (GST) activity. Bars with different letters are significantly different 
(P<0.05). See text for details. 
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5-Azaytidine or Curcumin (µM) 
5-Azacytidine(control) treatment time(72 hrs)
5-Azacytidine(control) treatment time(144 hrs)
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Curcumin treatment time(144 hrs)
